Table 1.

The patients’ characteristics

Case	Eye affected	Durations (days)	Medical treatment before cyclophotocoagulation	Presenting IOP (mmHg)	VA (LogMAR)
1	Left	7	1% pilocarpine QID, 2% carteolol Q12H, 0.2% Brimonidine BID	43.2	HM
2	Left	11	1% pilocarpine Q2H, 1% Brinzolamide TID, 0.2% Brimonidine BID, oral Methazolamide 25 mg BID, intravenous 20% mannitol 250 ml QD	43.6	1.0
3	Right	7	1% pilocarpine QID, 2% carteolol Q12H, 0.2% Brimonidine BID, intravenous 20% mannitol 400 ml QD	45.0	2.0
4	Left	6	1% pilocarpine QID, 2% carteolol Q12H, 1% Brinzolamide TID, oral Methazolamide 50 mg BID, intravenous 20% mannitol 400 ml Q12H	48.6	0.9
5	Right	23	1% pilocarpine QID, 2% carteolol Q12H, 1% Brinzolamide TID, oral Methazolamide 25 mg BID, intravenous 20% mannitol 250 ml Q12H	54.2	HM
6	Left	20	1% pilocarpine TID, 2% carteolol Q12H, 1% Brinzolamide TID, 0.2% Brimonidine BID, oral Methazolamide 50 mg BID	58.7	HM
7	Left	15	1% pilocarpine QID, 2% carteolol Q12H, 1% Brinzolamide TID, 0.2% Brimonidine BID, oral Methazolamide 25 mg BID	44.8	FC
8	Right	17	1% pilocarpine QID, 1% Brinzolamide TID, 0.2% Brimonidine BID, oral Methazolamide 25 mg BID, intravenous 20% mannitol 250 ml QD	47.0	1.0
9	Right	12	1% pilocarpine QID, 2% carteolol Q12H, 1% Brinzolamide TID, 0.2% Brimonidine BID, oral Methazolamide 25 mg BID, intravenous 20% mannitol 400 ml QD	50.0	FC

IOP: intraocular pressure, VA: vision acuity, HM: hand movement, FC: finger counting.

Case 1, 6 and 7 were not administered mannitol for systemic disease (such as renal dysfunction, cardiac insufficiency, etc), case 2 and 8 were not administered beta-blocker for atrioventricular block, case 1 and 3 were not administered carbonic anhydrase inhibitors for medication allergy.